The global market for Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) was estimated to be worth US$ 9591.9 million in 2023 and is forecast to a readjusted size of US$ 24730 million by 2030 with a CAGR of 14.7% during the forecast period 2024-2030

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) - Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) by region & country, by Type, and by Application.

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx).

Market Segmentation

Scope of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) - Market Report

Report Metric	Details
Report Name	Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) - Market
Forecasted market size in 2030	US$ 24730 million
CAGR	14.7%
Forecasted years	2024 - 2030
Segment by Type:	PCR In-situ Hybridization Immunohistochemistry Sequencing Others
Segment by Application	Oncology Neurological Disorders Cardiovascular Disease Immunological Disorders Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Qiagen NV, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH, Pfizer
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) - Market size in 2030?

Ans: The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) - Market size in 2030 will be US$ 24730 million.

Who are the main players in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) - Market report?

Ans: The main players in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) - Market are Qiagen NV, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH, Pfizer

What are the Application segmentation covered in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) - Market report?

Ans: The Applications covered in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) - Market report are Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Others

What are the Type segmentation covered in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) - Market report?

Ans: The Types covered in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) - Market report are PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others

1 Market Overview

1.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Introduction

1.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Forecast

1.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Trends & Drivers

1.3.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industry Trends

1.3.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers & Opportunity

1.3.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Challenges

1.3.4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Revenue Ranking (2023)

2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Company (2019-2024)

2.3 Key Companies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Manufacturing Base Distribution and Headquarters

2.4 Key Companies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Offered

2.5 Key Companies Time to Begin Mass Production of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx)

2.6 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Competitive Analysis

2.6.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 PCR

3.1.2 In-situ Hybridization

3.1.3 Immunohistochemistry

3.1.4 Sequencing

3.1.5 Others

3.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type

3.2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, by Type (2019-2030)

3.2.3 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Oncology

4.1.2 Neurological Disorders

4.1.3 Cardiovascular Disease

4.1.4 Immunological Disorders

4.1.5 Others

4.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application

4.2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, by Application (2019-2030)

4.2.3 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region

5.1.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region (2019-2024)

5.1.3 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region (2025-2030)

5.1.4 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2030

5.2.2 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2030

5.3.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2030

5.4.2 Asia Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2030

5.5.2 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2030

5.6.2 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value

6.3 United States

6.3.1 United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2030

6.3.2 United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2030

6.4.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2030

6.5.2 China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

6.5.3 China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2030

6.6.2 Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2030

6.7.2 South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2030

6.8.2 Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019-2030

6.9.2 India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

6.9.3 India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Qiagen NV

7.1.1 Qiagen NV Profile

7.1.2 Qiagen NV Main Business

7.1.3 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

7.1.4 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2024)

7.1.5 Qiagen NV Recent Developments

7.2 GE Healthcare

7.2.1 GE Healthcare Profile

7.2.2 GE Healthcare Main Business

7.2.3 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

7.2.4 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2024)

7.2.5 GE Healthcare Recent Developments

7.3 Agilent Technologies

7.3.1 Agilent Technologies Profile

7.3.2 Agilent Technologies Main Business

7.3.3 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

7.3.4 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2024)

7.3.5 F Hoffman La Roche Recent Developments

7.4 F Hoffman La Roche

7.4.1 F Hoffman La Roche Profile

7.4.2 F Hoffman La Roche Main Business

7.4.3 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

7.4.4 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2024)

7.4.5 F Hoffman La Roche Recent Developments

7.5 Foundation Medicine

7.5.1 Foundation Medicine Profile

7.5.2 Foundation Medicine Main Business

7.5.3 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

7.5.4 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2024)

7.5.5 Foundation Medicine Recent Developments

7.6 Thermo Fisher Scientific Inc.

7.6.1 Thermo Fisher Scientific Inc. Profile

7.6.2 Thermo Fisher Scientific Inc. Main Business

7.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

7.6.4 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2024)

7.6.5 Thermo Fisher Scientific Inc. Recent Developments

7.7 Leica Biosystems Nussloch GmBH

7.7.1 Leica Biosystems Nussloch GmBH Profile

7.7.2 Leica Biosystems Nussloch GmBH Main Business

7.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

7.7.4 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2024)

7.7.5 Leica Biosystems Nussloch GmBH Recent Developments

7.8 Pfizer

7.8.1 Pfizer Profile

7.8.2 Pfizer Main Business

7.8.3 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

7.8.4 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (US$ Million) & (2019-2024)

7.8.5 Pfizer Recent Developments

8 Industry Chain Analysis

8.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industrial Chain

8.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Model

8.5.2 Sales Channel

8.5.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Thermo Fisher Scientific Inc

Leica Biosystems Nussloch GmBH

Pfizer Inc

List of Tables

Table 1. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Trends

Table 2. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers & Opportunity

Table 3. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Challenges

Table 4. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints

Table 5. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Type

Table 9. Key Companies Time to Begin Mass Production of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx)

Table 10. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region (2019-2024) & (%)

Table 27. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, (2025-2030) & (US$ Million)

Table 31. Qiagen NV Basic Information List

Table 32. Qiagen NV Description and Business Overview

Table 33. Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

Table 34. Revenue (US$ Million) in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business of Qiagen NV (2019-2024)

Table 35. Qiagen NV Recent Developments

Table 36. GE Healthcare Basic Information List

Table 37. GE Healthcare Description and Business Overview

Table 38. GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

Table 39. Revenue (US$ Million) in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business of GE Healthcare (2019-2024)

Table 40. GE Healthcare Recent Developments

Table 41. Agilent Technologies Basic Information List

Table 42. Agilent Technologies Description and Business Overview

Table 43. Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

Table 44. Revenue (US$ Million) in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business of Agilent Technologies (2019-2024)

Table 45. Agilent Technologies Recent Developments

Table 46. F Hoffman La Roche Basic Information List

Table 47. F Hoffman La Roche Description and Business Overview

Table 48. F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

Table 49. Revenue (US$ Million) in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business of F Hoffman La Roche (2019-2024)

Table 50. F Hoffman La Roche Recent Developments

Table 51. Foundation Medicine Basic Information List

Table 52. Foundation Medicine Description and Business Overview

Table 53. Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

Table 54. Revenue (US$ Million) in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business of Foundation Medicine (2019-2024)

Table 55. Foundation Medicine Recent Developments

Table 56. Thermo Fisher Scientific Inc. Basic Information List

Table 57. Thermo Fisher Scientific Inc. Description and Business Overview

Table 58. Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

Table 59. Revenue (US$ Million) in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business of Thermo Fisher Scientific Inc. (2019-2024)

Table 60. Thermo Fisher Scientific Inc. Recent Developments

Table 61. Leica Biosystems Nussloch GmBH Basic Information List

Table 62. Leica Biosystems Nussloch GmBH Description and Business Overview

Table 63. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

Table 64. Revenue (US$ Million) in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business of Leica Biosystems Nussloch GmBH (2019-2024)

Table 65. Leica Biosystems Nussloch GmBH Recent Developments

Table 66. Pfizer Basic Information List

Table 67. Pfizer Description and Business Overview

Table 68. Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Products, Services and Solutions

Table 69. Revenue (US$ Million) in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business of Pfizer (2019-2024)

Table 70. Pfizer Recent Developments

Table 71. Key Raw Materials Lists

Table 72. Raw Materials Key Suppliers Lists

Table 73. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Downstream Customers

Table 74. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Distributors List

Table 75. Research Programs/Design for This Report

Table 76. Key Data Information from Secondary Sources

Table 77. Key Data Information from Primary Sources

Table 78. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Picture

Figure 2. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value (2019-2030) & (US$ Million)

Figure 4. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Report Years Considered

Figure 5. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue in 2023

Figure 7. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. PCR Picture

Figure 9. In-situ Hybridization Picture

Figure 10. Immunohistochemistry Picture

Figure 11. Sequencing Picture

Figure 12. Others Picture

Figure 13. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value Market Share by Type, 2023 & 2030

Figure 15. Product Picture of Oncology

Figure 16. Product Picture of Neurological Disorders

Figure 17. Product Picture of Cardiovascular Disease

Figure 18. Product Picture of Immunological Disorders

Figure 19. Product Picture of Others

Figure 20. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 21. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value Market Share by Application, 2023 & 2030

Figure 22. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value (2019-2030) & (US$ Million)

Figure 23. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2023 VS 2030

Figure 24. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value (2019-2030) & (US$ Million)

Figure 25. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2023 VS 2030

Figure 26. Asia Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value (2019-2030) & (US$ Million)

Figure 27. Asia Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2023 VS 2030

Figure 28. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value (2019-2030) & (US$ Million)

Figure 29. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2023 VS 2030

Figure 30. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value (2019-2030) & (US$ Million)

Figure 31. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Country (%), 2023 VS 2030

Figure 32. Key Countries/Regions Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value (%), (2019-2030)

Figure 33. United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, (2019-2030) & (US$ Million)

Figure 34. United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

Figure 35. United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application (%), 2023 VS 2030

Figure 36. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, (2019-2030) & (US$ Million)

Figure 37. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

Figure 38. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application (%), 2023 VS 2030

Figure 39. China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, (2019-2030) & (US$ Million)

Figure 40. China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

Figure 41. China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application (%), 2023 VS 2030

Figure 42. Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, (2019-2030) & (US$ Million)

Figure 43. Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

Figure 44. Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application (%), 2023 VS 2030

Figure 45. South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, (2019-2030) & (US$ Million)

Figure 46. South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

Figure 47. South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application (%), 2023 VS 2030

Figure 48. Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, (2019-2030) & (US$ Million)

Figure 49. Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

Figure 50. Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application (%), 2023 VS 2030

Figure 51. India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value, (2019-2030) & (US$ Million)

Figure 52. India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Type (%), 2023 VS 2030

Figure 53. India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Sales Value by Application (%), 2023 VS 2030

Figure 54. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industrial Chain

Figure 55. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Manufacturing Cost Structure

Figure 56. Channels of Distribution (Direct Sales, and Distribution)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions